← Search another drug
PatientPulse · by PatientPartner
Keytruda pembrolizumab
High confidence
Approximately 55 public patient conversations, blog posts, forum threads, and review pages analyzed, spanning 2017 to 2026.
Executive intelligence
The signal that moves starts & adherence
42%Positive sentiment in discussion
100,432FDA adverse-event reports
87%Flagged serious
50%Reports name female patients
The single most actionable insight: endocrine side effects (hypothyroidism, adrenal insufficiency, ICI-induced diabetes) are the #1 driver of mid-treatment distress and discontinuation consideration, yet patients report poor proactive communication from oncology teams at the moment those lab values shift.
- Keytruda's efficacy narrative is powerfully patient-driven, with NED and remission stories circulating widely across forums and blogs, creating strong pull among newly diagnosed patients weighing immunotherapy vs. chemotherapy.
- Endocrine immune-related adverse events (hypothyroidism, adrenal insufficiency, ICI-induced diabetes) dominate mid-treatment distress conversations and are the most cited reason patients consider or actually pursue discontinuation.
- Cost and coverage anxiety, especially the question of paying out-of-pocket after 2-year insurance limits, is a persistent and emotionally charged thread that shapes both initiation and continuation decisions across income levels.
- The quality-of-life trade-off framing (Keytruda vs. chemo) is the dominant decision lens at treatment initiation, but patients report that oncology teams underestimate how burdensome cumulative low-grade side effects become over months of maintenance therapy.